![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RL Gellman, JA Kallianos and JO McNamara
We sought to elucidate the receptor subtype through which endogenous norepinephrine suppresses epileptogenesis in the rat kindling model. To this end we examined the effects of systemically administered selective antagonists and an alpha-2 agonist on kindling development and on kindled seizures. The alpha-2 adrenergic antagonists idazoxan, yohimbine and rauwolscine (0.1-10.0 mg/kg i.p.) dose-dependently facilitated amygdala kindling development. Central administration of idazoxan (20 micrograms/40 microliter i.c.v.) produced an equivalent facilitation. The facilitation was selective for alpha-2 antagonists because neither the alpha-1 antagonist corynanthine (0.1-10.0 mg/kg i.p.), nor the beta antagonist propranolol (0.1-10.0 mg/kg i.p.), nor the selective beta-1 antagonist ICI 89,406 (10 micrograms/40 microliter i.c.v.) nor the beta-2 antagonist ICI 118,551 (0.5-5.0 mg/kg i.p.) modified kindling development. The alpha-2 agonist clonidine (0.01-0.2 mg/kg i.p.) dose-dependently suppressed kindling development. In contrast to the effects on kindling development, neither the alpha-2 antagonists nor clonidine modified seizures elicited from previously kindled animals. We interpret the data to indicate that endogenous norepinephrine suppresses kindling development by activation of postsynaptic alpha-2 receptors. The selective inhibition of kindling development, but not kindled seizures, suggests that alpha-2 agonists may be effective antiepileptogenic, but not anticonvulsant, agents.
This article has been cited by other articles:
|
|
 |
|
  D. Weinshenker, P. Szot, N. S. Miller, N. C. Rust, J. G. Hohmann, U. Pyati, S. S. White, and R. D. Palmiter Genetic Comparison of Seizure Control by Norepinephrine and Neuropeptide Y J. Neurosci., October 1, 2001; 21(19): 7764 - 7769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Weinshenker, P. Szot, N. S. Miller, and R. D. Palmiter alpha 1 and beta 2 Adrenoreceptor Agonists Inhibit Pentylenetetrazole-Induced Seizures in Mice Lacking Norepinephrine J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1042 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Janumpalli, L. S. Butler, L. B. MacMillan, L. E. Limbird, and J. O. McNamara A Point Mutation (D79N) of the alpha 2A Adrenergic Receptor Abolishes the Antiepileptogenic Action of Endogenous Norepinephrine J. Neurosci., March 15, 1998; 18(6): 2004 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stasheff, W. Anderson, S Clark, and W. Wilson NMDA antagonists differentiate epileptogenesis from seizure expression in an in vitro model Science, August 11, 1989; 245(4918): 648 - 651. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
